Contents
Issue 127 • February 2023
In association with
In association with
In Depth
Will 2023 be a milestone year for CRISPR gene therapies?
Tracking the ups and downs of pharma deals
Regulation starts to catch up with AI in pharma
Next on trial diversity: Embracing participants with cognitive impairment
Digital twins: The next frontier to ease clinical trial conduct
CMO Moves: Regulatory catalysts for drug manufacturing-January
Comment
High hopes for mRNA anti-cancer vaccines with early successes
Cell therapies might revolutionise treatment for multiple sclerosis patients
Downturn for top biopharma companies as Covid-19 vaccine demand falls in Q3
Inflation threatens supply of life-saving generics to Europe
Data is the key to a safer and more controlled pharmaceutical cold-chain